St. Vincenz-Krankenhaus GmbH — Clinical Trial Site

24 Registered trials

10 Currently recruiting

Organisation

St. Vincenz-Krankenhaus GmbH

Location

Paderborn, Germany

Identifier

ORG-100021306

Address

Rottstrasse 11, 45711, Germany

Departments

#3127: Frauen- und Kinderklinik St. Louise
Apotheke
Clinic for Gynecology and Obstetrics, Gynecology and Cancer Center
Department of Gynecology and Obstetrics
Frauen- und Kinderklinik
Frauen- und Kinderklinik St. Louise
Frauenklinik
Frauenklinik St. Louise - St. Vincenz Krankenhaus GmbH
Gynacology (Frauen- und Kinderklinik)
Gynäkologie und Geburtshilfe
Gynecology and Obstetrics
Hämatologie/Onkologie/Rheumatologie
Klinik fur Gynakologie und Geburtshilfe
Klinik für Gynäkologie und Geburtshilfe - Brustzentrum
Klinik für Gynäkologie und Geburtshilfe Kooperatives Brustzentrum Paderborn
Klinik für Gynäkologie und Geburtshilfe; Kooperatives Brustzentrum Paderborn Gyn. Krebszentrum
Medizinische Klinik I
Medizinische Klinik II (Kardiologie & Internistische Intensivmedizin)
NA

Clinical trials at this site (24)

Search interface

A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting

2025-524498-17-00 Pretreated Unresectable Locally Advanced or Metastatic 10 2026-05-08
A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E… Recruiting

2024-518777-34-00 B7-H4-Selected Advanced/Metastatic Endometrial Cancer. 5 2026-02-11
A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in… Recruiting

2022-501152-28-00 Breast Cancer 4 2022-12-21
Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose… Recruiting

2024-516066-11-00 Patients with newly diagnosed, histologically confirmed 5 2022-08-31
A clinical study of sac-TMT in people with breast cancer (MK-2870-032) Recruiting

2024-520190-12-00 Breast Cancer: triple negative breast cancer (TNBC) and 5 2025-11-10
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting

2023-508162-15-00 Chronic HF and comorbid impairment of kidney function w 5 2024-07-12
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Atrial Fibrillation 5 2023-10-31
CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE… Recruiting

2022-500764-35-00 Patients with advanced HER2-negative, hormone receptor 6 2022-10-13
A Study to Test Inavolisib Treatments in Patients with Early-Stage, PIK3CA-Mutated Breast Cancer Ended

2024-518811-20-00 Early-Stage, PIK3CA-Mutated Breast Cancer (BC) 4 2025-09-30
A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. Ended

2022-503001-38-01 HR-positive HER-2- negative Breast Cancer 5 2025-07-08
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+… Ended

2024-514458-61-01 HER2+ early breast cancer 4 2024-02-05
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients with Hormone Recepto… Ended

2022-502322-41-00 Metastatic breast cancer 5 2023-09-12
A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C… Ended

2023-505552-22-00 Stage I-III Triple-negative Breast Cancer with residual 5 2023-02-24
DESTINY-Breast11 will compare trastuzumab deruxtecan (T-DXd) alone or in sequence with other medications, known as THP, with standard of car… Ended

2023-505210-18-00 Early stage HER2-positive breast cancer (T stage >= T3, 5 2021-12-17
A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended

2023-503990-39-00 Estrogen Receptor-Positive, HER-2 negative Advanced Bre 5 2021-09-30
FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for lo… Ended

2024-518077-34-00 locally advanced rectal cancer 5 2020-09-30
Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2… Ended

2023-505042-25-00 Locally advanced (inoperable) or metastatic HR+/HER2 br 5 2020-05-05
Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined… Ended

2024-511577-29-01 intermediate and high-risk rectal cancer 5 2020-03-13
Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended

2023-506921-12-00 ER+/HER2- Breast Cancer 5 2018-12-27
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
CIRCULATE Ended

2023-506715-18-00 colon cancer stage II, rectal cancer stage II 5 2019-12-04
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended

2023-508472-11-00 Patients with early breast cancer 5 2018-06-13